

## The Boolean Kinetics of Signal Transduction: Supplementary Material

Equations of the LAC\_SIM model of the *E.coli* Lac operon (Figure 1):

$$v1 = Vm1 / (1 + (RPf/Ki1)^{n1})$$

where RPf is free (unbound) concentration of lac repressor

$$v2 = \beta\text{-Gal} * k2$$

where  $\beta\text{-Gal}$  is concentration of  $\beta$ -galactosidase

$$v3 = Vm3 * \text{lactoseC} / (\text{lactoseC} + Km3)$$

where lactoseC is cellular lactose concentration;  $Vm3 = \beta\text{-Gal} * TO3$

$$v4 = \text{lactoseE} * k4$$

where lactoseE is extracellular lactose concentration

$$v5 = \text{permease} * k5$$

where permease is concentration of galactoside permease

$$v6 = Vm6 * \text{lactoseE} / (\text{lactoseE} + Km6) / (1 + I/Ki6)$$

where  $Vm6 = \text{permease} * TO6$  and I is an inhibitor of facilitated transport.

$$v7 = \text{lactoseC} * k7$$

$k2, k4, k5$  and  $k7$  are first-order rate constants for their respective reactions.  $Vm1, Vm3$  and  $Vm6$  are maximal velocities;  $Vm1$  is a constant, and  $Vm3$  and  $Vm6$  are the product of the respective enzyme concentrations and their turnover numbers,  $TO3$  and  $TO6$ , respectively;  $Km3$  and  $Km6$  are Michaelis constants;  $Ki1$  and  $Ki6$  are noncompetitive inhibition constants;  $n1$  and  $n3$  are Hill constants.

Then lactoseE is constant

$$d[\text{lactoseC}]/dt = v4 + v6 - v3 - v7$$

$$d[\beta\text{-Gal}]/dt = v1 - v2$$

$$d[\text{permease}]/dt = v1 - v5$$

$$RPf = RPt / (1 + (\text{lactoseC}/Ki3)^{n3})$$

where RPt is total (free + alloactose-bound) concentration of lac repressor.

Parameter values used for the simulations discussed in the main text were:  $k2=1.0; k4=0.05; k5=4.5; k7=0.05; Vm1=100; TO3=0.167; TO6=0.98; Km3=0.2; Km6=0.05; Ki1=1.0$ .

Equations of the MAPK\_SIM model of the human MAPK signalling pathway (see figure 4):

$$v1 = Vm1 * cfos / (cfos + Km1) / (1 + cyclinD/Ki1)$$

$$v2 = \text{cyclinD} * k2$$

$$v3 = Vm3 * (\text{ras}/Km3)^{n3} / (1 + (\text{ras}/Km3)^{n3})$$

where ras indicates the ras-GTP complex.

$$v4 = Vm4 * \text{EGF}/Km4 / (1 + \text{EGF}/Km4) / (1 + \text{spr}/Ki4) / (1 + I4/Kinc)$$

where spr is the sprouty protein [25], and I4 is an inhibitor of the EGF receptor tyrosine kinase, e.g. erlotinib [26].

$$v5 = Vm5 * \text{Grb2}/Km5 / (1 + \text{Grb2}/Km5)$$

$$v6 = \text{Grb2} * k6$$

$$v7 = Vm7 * \text{MEKP}/Km7 / (1 + \text{MEKP}/Km7) / (1 + \text{spr}/Ki7)$$

where MEKP is the active, phosphorylated form of MEK.

$$v8 = \text{ras} * k8$$

$$v9 = Vm9 * \text{raf}/Km9 / (1 + \text{raf}/Km9) / (1 + \text{ERKP}/Ki9) / (1 + I9/Ki8)$$

where ERKP is the phosphorylated form of ERK and I9 is a raf kinase inhibitor, e.g. sorafenib [27].

$$v10 = Vm10 * \text{MEKP}/Km10 / (1 + \text{MEKP}/Km10)$$

$$v_{11} = ERKP * k_{11}$$

$k_2$ ,  $k_6$ ,  $k_8$  and  $k_{11}$  are first-order rate constants for their respective reactions.  $V_{m1}$ ,  $V_{m3}$ ,  $V_{m4}$ ,  $V_{m5}$ ,  $V_{m7}$ ,  $V_{m9}$  and  $V_{m10}$  are maximal velocities;  $K_{m1}$ ,  $K_{m3}$ ,  $K_{m4}$ ,  $K_{m5}$ ,  $K_{m7}$ ,  $K_{m9}$  and  $K_{m10}$  are Michaelis constants;  $K_{i1}$ ,  $K_{i4}$ ,  $K_{i7}$ ,  $K_{i8}$ ,  $K_{i9}$  and  $K_{inc}$  are noncompetitive inhibition constants;  $n_3$  is a Hill constant.

Then

$$d[Grb2]/dt = v_4 - v_6$$

$$d[ras]/dt = v_5 + v_{21} - v_8; \text{ note: } v_{21} \text{ is a cross-talk signal from the PI3K pathway, discussed below.}$$

$$d[raf]/dt = v_3 - v_9$$

$$d[MEKP]/dt = v_9 - v_{10}$$

$$d[ERKP]/dt = v_{10} - v_7 - v_{11}$$

$$d[cfos]/dt = v_7 - v_1$$

$k_2$ ,  $k_6$ ,  $k_8$  and  $k_{11}$  are first-order rate constants for their respective reactions.  $V_{m1}$ ,  $V_{m3}$ ,  $V_{m4}$ ,  $V_{m5}$ ,  $V_{m7}$ ,  $V_{m9}$  and  $V_{m10}$  are maximal velocities;  $K_{m1}$ ,  $K_{m3}$ ,  $K_{m4}$ ,  $K_{m5}$ ,  $K_{m7}$ ,  $K_{m9}$  and  $K_{m10}$  are Michaelis constants;  $K_{i1}$ ,  $K_{i4}$ ,  $K_{i7}$  and  $K_{i9}$  are noncompetitive inhibition constants;  $n_3$  is a Hill constant.

$k_2=1.6$ ;  $k_6=.05$ ;  $k_8=.028$ ;  $k_{11}=.02$ ;  $V_{m1}=19.4$ ;  $V_{m3}=10$ ;  $V_{m4}=.33$ ;  $V_{m5}=50$ ;  $V_{m7}=20$ ;  $V_{m9}=10$ ;  $V_{m10}=20$ ;  $K_{m1}=1$ ;  $K_{m3}=30$ ;  $K_{m4}=1$ ;  $K_{m5}=3.5$ ;  $K_{m7}=10$ ;  $K_{m9}=2$ ;  $K_{m10}=1$ ;  $K_{i1}=10$ ;  $K_{i3}=1$ ;  $k_{i4}=1$ ;  $K_{i5}=1$ ;  $K_{i7}=1$ ;  $K_{i9}=400$ ;  $K_{i10}=1$ ;  $n_3=4$ .

Equations of the Akt\_SIM model of the human Akt (PI3K) signalling pathway (Figure 7):

$$v_{12} = V_{m12} * PDGF/K_{m12} / (1 + PDGF/K_{m12})$$

$$v_{13} = PI3K * k_{13}$$

$$v_{14} = V_{m14} * PI3K/K_{m14} / (1 + PI3K/K_{m14}) / (1 + I_{14}/K_{i14})$$

where  $I_{14}$  is an inhibitor of PI3 kinase, e.g. LY294002 [28].

$$v_{15} = V_{m15} * Akt/K_{m15} / (1 + Akt/K_{m15})$$

$$v_{16} = V_{m16} * mTOR/K_{m16} / (1 + mTOR/K_{m16})$$

$$v_{17} = eIF4E * k_{17}$$

$$v_{18} = V_{m18} * mTOR/K_{m18} / (1 + mTOR/K_{m18})$$

$$v_{19} = p70S6K * k_{19}$$

$$v_{20} = V_{m20} * eIF4E/K_{a20} / (1 + eIF4E/K_{a20}) * p70S6K/K_{b20} / (1 + p70S6K/K_{b20})$$

$$v_{21} = PI3K * k_{21}$$

$$v_{22} = ras * k_{22}$$

$k_{13}$ ,  $k_{17}$ ,  $k_{19}$ ,  $k_{21}$  and  $k_{22}$  are first-order rate constants for their respective reactions.  $V_{m12}$ ,  $V_{m14}$ ,  $V_{m15}$ ,  $V_{m16}$ ,  $V_{m18}$  and  $V_{m20}$  are maximal velocities;  $K_{m12}$ ,  $K_{m14}$ ,  $K_{m15}$ ,  $K_{m16}$  and  $K_{m18}$  are Michaelis constants;  $K_{a20}$  and  $K_{b20}$  are dissociation constants for binding of eIF4E and p70S6K respectively;  $K_{i14}$  is a noncompetitive inhibition constant.

Then

$$d[PI3K] = v_{12} + v_{22} - v_{13}$$

$$d[Akt] = v_{14} - v_{15}$$

$$d[mTOR] = v_{15} - v_{16} - v_{18}$$

$$d[eIF4E] = v_{16} - v_{17}$$

$$d[p70S6K] = v_{18} - v_{19}$$

Parameter values used for the simulations used in the main text were:  $k_{13}=.05$ ;  $k_{17}=.2$ ;  $k_{19}=.1$ ;  $k_{21}=.01$ ;  $k_{22}=.01$ ;  $V_{m12}=.66$ ;  $V_{m14}=2$ ;  $V_{m15}=4$ ;  $V_{m16}=5$ ;  $V_{m18}=3$ ;  $V_{m20}=6$ ;  $K_{m12}=1$ ;  $k_{m14}=5$ ;  $K_{m15}=5$ ;  $K_{m16}=5$ ;  $K_{m18}=4$ ;  $K_{m20}=1$ .

**Copyright:** ©2017 Jackson RC. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.